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Antimicrobial peptides have been found in mollusks and other sea animals. In this report, a crude extract
of the marine snail Cenchritis muricatuswas evaluated against human pathogens responsible for multiple
deleterious effects and diseases. A peptide of 1485.26 Da was puriﬁed by reversed-phase HPLC and
functionally characterized. This trypsinized peptide was sequenced by MS/MS technology, and
a sequence (SRSELIVHQR), named Cm-p1 was recovered, chemically synthesized and functionally
characterized. This peptide demonstrated the capacity to prevent the development of yeasts and
ﬁlamentous fungi. Otherwise, Cm-p1 displayed no toxic effects against mammalian cells. Molecular
modeling analyses showed that this peptide possible forms a single hydrophilic a-helix and the probable
cationic residue involved in antifungal activity action is proposed. The data reported here demonstrate
the importance of sea animals peptide discovery for biotechnological tools development that could be
useful in solving human health and agribusiness problems.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
In the last three decades, several agents of new infectious
diseases have been identiﬁed, some of which are responsible for
entirely novel and life-threatening disorders [1,2]. A lack of new
antibiotics for treatment of illnesses associated with the appear-
ance of multi-drug-resistant strains has demanded the urgent
development of innovative strategies for the control of microor-
ganisms [3]. Certain human fungal infections, such as those caused
by Aspergillus fumigatus, Cryptococcus neoformans, Histoplasma
capsulatum and Candida albicans, are gaining importance due to the
increasing number of immunocompromised patients [4]. Thus far,
existing treatments for these infections are limited to only a small
number of antifungal drugs, such as azoles, echinocandins, and
polyenes [5]. Indeed, pathogenic fungi possess many complicated
mechanisms for resisting these drugs, constituting a critical-González).
nder the Elsevier OA license.challenge for antifungal therapy. The development of novel thera-
peutic agentsmay overcome this problem [6]. Additionally, because
the search for original and useful antifungals has been limited,
especially for drug-resistant pathogenic fungi, screening for novel
antifungal peptides in multiple biomes could help to reduce
infections in plants and animals.
Antimicrobial peptides (AMPs) can exhibit a broad spectrum of
activities against a wide range of microorganisms, including Gram-
positive and Gram-negative bacteria [7], yeasts [8], fungi [9],
viruses [10], protozoa [11] and parasites, such as nematodes [12].
Several mechanisms of action have been proposed for these
molecules [13], which indicate that many of them have more than
one antimicrobial target at the cellular level [14]. Initially, peptides
can interact with the cell membrane, causing an increase in
permeability concomitant with a loss of membrane function.
Moreover, peptides can affect intracellular targets, such as the
nucleus and its DNA, leading to apoptosis [15].
There are multiple sources of antimicrobial peptides, including
plants, mammals and invertebrates. Invertebrates base their
C. López-Abarrategui et al. / Biochimie 94 (2012) 968e974 969humoral defense against infectious agents on a wide and effective
repertoire of AMPs that may interact directly with microbes or with
their toxic molecules [16]. Due to this fact, many researchers have
used mollusks and other marine sea animals as sources for the
development of novel antimicrobials [16]. Mollusks are an abun-
dant and signiﬁcant group in the trophic chain of the animal
kingdom. Among the mollusks, gastropods, including snails and
slugs, represent the most abundant class. Snails in particular are
successful animals from an evolutionary point of view, due to their
capacity to adapt to different environments and to reach dry land
[17]. Although antimicrobial peptides have been puriﬁed from
several marine invertebrates, only a few have been reported in
mollusks [16]. Most research has focused on species such asMytilus
edulis Linnaeus, 1758 and Mytilus galloprovincialis Lamarck, 1819.
These species are capable of synthesizing defensins, mytilins and
the antifungal peptide mitomycin [16].
Here, we report the isolation and biochemical characterization
of different forms of the antimicrobial peptide fragments from C.
muricatus. To expand our functional analyses, a lower-molecular-
weight peptide, Cm-p1, was synthesized and further evaluated
regarding its antimicrobial actions toward multiple fungi and
mammalian cells. An in silico evaluationwas also conducted, which
showed that the molecular surface and the presence of several
residues could be essential for the peptide’s antifungal activity.
2. Materials and methods
2.1. Extraction and isolation of proteinaceous compounds
C. muricatus Linnaeus, 1758 (Mollusca: Gastropoda) snails were
hand-collected on the northern coast of Havana, Cuba. C.muricatus
snails were homogenized in a solution containing 0.6 M NaCl and
0.1% HCl (2:1 [w/v]) in a blender. The homogenate was centrifuged
at 10,000  g for 30 min at 4 C. Soluble proteins were precipitated
with (NH4)2SO4 at 100% saturation with constant stirring for 1 h at
4 C. After centrifuging again at 10,000  g for 30 min at 4 C, the
precipitate was resuspended in 10 mM TriseHCl buffer, pH 8.0 and
was further desalted using PD MidiTrap G-10 columns (GE
Healthcare, USA). The resulting desalted, protein-rich fraction was
separated into low- (<10 kDa) and high-molecular-weight fractions
(>10 kDa) using Amicon Ultra-15 (10 K) centrifugal ﬁlter devices
(Millipore, USA). The low-molecular-weight fraction was lyophi-
lized, and 3.0 mg of the dry fraction was dissolved in 0.1% tri-
ﬂuoroacetic acid (TFA) and then applied onto a reversed-phase
HPLC Vydac C18-TP analytical column (Hesperia, CA, USA) equili-
brated with 0.1% TFA. Retained proteins were eluted with a linear
methanol gradient (0e100%) at a ﬂow rate of 1.0 ml min1. Protein
detection was performed at 280 nm.
2.2. Protein identiﬁcation by mass spectrometry
After elution, a peptide digestion was performed using
sequencing grade modiﬁed trypsin (Promega, USA) according to
[18] with minor modiﬁcations. Brieﬂy, 600 ng of buffered trypsin
was added to the peptide and incubated on ice for 30 min. Then
40 mL of 50 mM NH4HCO3 was added, and the solution was incu-
bated at 37 C for 22 h. The digestion supernatant was collected and
stored at 20 C. The peptides derived from the tryptic digestion
were analyzed using an UltraFlex III MALDI-TOF/TOF (Bruker Dal-
tonics) precisely calibrated with peptide calibration standard II
(Bruker Daltonics). A 1 mL sample was mixed with 3 mL of matrix
solution (1% [w/v] a-cyano-4-hydroxycinnamic acid, 3% [v/v] tri-
ﬂuoroacetic acid and 50% [v/v] acetonitrile) and applied onto
a MALDI target plate (1 mL in duplicate). After crystallization at
room temperature, samples were analyzed using a spectrometeroperated in reﬂector mode for MS acquisitions and LIFT mode for
tandem MS (MS/MS). Protein identiﬁcation was achieved by
peptide mass ﬁngerprinting (PMF) and manual de novo sequencing.
The sequenced peptide was directly aligned at the non-redundant
protein database (NCBI) and APD data bank similarity searches
with bioactive peptides.
2.3. Amino acid sequence analysis by automated Edman
degradation
The amino acid sequences of the peptides were analyzed by
automated Edman degradation. Microsequencing was performed
using a HewlettePackard 1000A protein sequencer equipped with
a HPLC system.
2.4. Peptide synthesis
Cm-p1 was synthesized by the solid-phase method using 9-
ﬂuorenyl-methoxycarbonyl chemistry [19], puriﬁed by reverse-
phase high-performance liquid chromatography to >98% purity
on an acetonitrile/H2O-TFA gradient and conﬁrmed by ion-spray
mass spectrometry (Micromass, Manchester, United Kingdom).
2.5. Determination of protein concentration
Protein concentrations were estimated using Coomassie Blue
staining [20]. Bovine serum albumin (BSA, 0.1 mgml1) was used as
the standard protein. All determinations were performed in
triplicate.
2.6. Bioassays against bacteria
Pathogenic bacteria were cultured in 2.0 mL of LB (Luria-Ber-
tani) broth (10 g L1 NaCl, 5 g L1 yeast extract and 45 g L1 bacto
peptone) for 18e24 h at 37 C. Protein-rich fractions, the puriﬁed
peptides and Cm-p1 were resuspended in distilled water and
ﬁltered through 0.22-mm nylon membranes. Dilution series for all
samples were prepared for an initial concentration of 200 mg ml1.
Samples were incubated for 6 h at 37 C with 5  106 CFU mL1 of
each bacterium tested. The assayed bacteria were Escherichia coli,
Staphylococcus aureus, Klebsiella sp., and Shigella sp. These micro-
organisms were obtained from the microbiology collection of the
Universidade Católica de Brasília. Sterile distilled water and chlor-
amphenicol (40 mg mL1) were used as the negative and positive
controls, respectively. Bacterial growth was determined spectro-
photometrically at 595 nm every hour during the incubation period
according to the Clinical and Laboratory Standards Institute (CLSI)
guidelines [21].
2.7. Bioassays against fungi
Bioassays against fungi were performed using the broth
microdilution method [22]. Fusarium oxysporum, Botrytis cinerea,
and Aspergillus niger were obtained from the Universidade Católica
Collection and were grown on solid medium potato dextrose broth
(Difco, USA). Liquid potato dextrose broth was used for the inhi-
bition assays against these fungi. Amphotericin-B (30 mg ml1) was
used as the positive control, and liquid potato dextrose broth was
used as the negative control. The bioassays against human patho-
genic yeast (Candida parapsilosis [ATCC 22019] and clinically iso-
lated strains of C. albicans [01U, 38U], C. neoformans [L26, L30],
Trichophyton mentagrophytes [28d, 28e] and Trichophyton rubrum
[329]) were performed in RPMI-1640 medium (Gibco BRL, USA).
Itraconazole and ﬂuconazole (0.5e4 mg ml1) were used as the
positive controls. Sterile distilled water was used as the negative
Fig. 1. A: HPLC reversed-phase chromatogram proﬁle (Vydac C18-TP) of the low-
molecular-weight fraction from Cenchritis muricatus snails. The diagonal line indi-
cates a linear methanol gradient. B: Mass spectrum of Cm-p1 isolated by HPLC in
a MALDI-ToF/ToF mass spectrometer operating in reﬂector mode and using a matrix of
a-cyano-4-hydroxycinnamic acid.
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tained according to the CLSI guidelines [23]. All tests were con-
ducted in triplicate.
2.8. Hemolytic assay
Cm-p1 hemolytic activity was evaluated by determining the
release of hemoglobin from an 8% suspension of fresh human
erythrocytes at 414 nm with an ELISA plate reader [24]. The assay
was performed with different concentrations of Cm-p1
(0e400 mg ml1). The percentage of hemolysis was calculated
using the following equation: % hemolysis ¼ [(Abs414 nm in the
peptide solution  Abs414 nm in PBS)/(Abs414 nm in 0.1% Triton X-
100  Abs414 nm in PBS)]  100. PBS was used as the negative
control, and Triton X-100 was used as the positive control. All
assays were performed in triplicate.
2.9. Cytotoxicity assay
The MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium
bromide; SigmaeAldrich, USA) assay was performed according to
[25]. RAW 264.7 murine macrophage-like cells (Rio de Janeiro Cell
Bank, Brazil)were plated at a concentration of 1105 cells perwell in
supplemented DMEM medium (4 mM glutamine, 10% FCS and
100 units/ml penicillin/streptomycin) and incubated with different
concentrations of peptides (0e400 mg ml1). After overnight incu-
bation, 10 ml of the MTT solution (5 mg mL1 in PBS) was added to
each well. Plates were incubated for 4 h in 5% CO2 at 37 C. The
generated blue formazan product was dissolved by the addition of
100 ml of 100% DMSO (Mallinckrodt Chemical, USA) per well. The
absorbance was monitored at 575 nm in an ELISA plate reader (Bio-
Tek, USA).
2.10. In silico analyses and molecular modeling
Initially, the physiochemical parameters were calculated using
the software ProtParam from the ExPASy server [26]. ClustalW was
used for aligning multiple sequences [27]. Helical wheel projection
was performed using the tool wheel from Gromacs software [28].
PSI-BLAST was used to ﬁnd the best templates for homology
modeling, but no results were returned. Alternatively, data mining
in a non-redundant database (APD2) highlighted reliable templates
[29]. The Protein Data Bank (PDB) structure 2RMI showed 22% of
identical residues and was thus used as the template. Template
utilized was astressin, which is able to binds to CRF-R1, a G-protein
coupled receptor that speciﬁcally binds corticotropin-releasing
hormone, at low nanomolar afﬁnity [30]. Fifty theoretical three-
dimensional peptide models were constructed with Modeller
v.9.8 [31] using the selected template. The ﬁnal models were
evaluated according to geometry, stereochemistry, and energy
distributions. PROSA II was utilized to analyze packing and solvent
exposure characteristics, and PROCHECK was used for additional
stereochemical quality checks [32,33]. Additionally, the root mean
square deviation (RMSD) was calculated from the overlap of Ca
traces and backbones onto the template structure using the
program 3DSS [34]. In order to conﬁrm model reliability, I-Tasser
and HHPred were also utilized for additional tridimensional model
construction according multiple-threading alignments and itera-
tive structural assembly simulations [35,55]. The RMSD among
model construct by MODELLER, I-Tasser and HHPred server were
calculated from the overlap of Ca traces and backbones onto the
template structure using the program 3DSS. Electrostatic surfaces
were calculated with the ABPS tool [36]. The protein structure was
visualized and analyzed with PyMOL (Delano Scientiﬁc) [37].3. Results
3.1. Identiﬁcation of antimicrobial peptides
First, the low-molecular-weight fraction (<10 kDa) of the 100%
ammonium sulfate precipitation pellet was applied onto
a reversed-phase HPLC C-18 column. Proteins and peptides were
eluted using a linear methanol gradient (0e100%), which yielded 14
fractions (Fig. 1A). The antimicrobial activities of all peaks were
evaluated against diverse pathogens. The second fraction was
eluted with 49.4% methanol and showed the highest antimicrobial
activity (data not shown).3.2. Amino acid sequencing and bioinformatics
To identify the fraction responsible for the higher activity,
fraction 2 was analyzed by MALDI-TOF/TOF. Fraction 2 consisted of
a single peptide that exhibited anm/z value of 1485 (Fig. 1B). It was
not possible to determine the sequence of this peptide by MS/MS;
therefore, the peptide was digested with trypsin. The digestion
yielded various peptide fragments that exhibited a more intense
ion at an m/z value of 1224 (data not shown). This ion was then
sequenced by MS/MS and yielded the 10-amino acid peptide
SRSELIVHQR. This peptide fragment was named Cm-p1 and was
compared to the AMP database [29]. The comparison of the primary
structure of Cm-p1 showed clear identity with other antimicrobial
peptides. Cm-p1 shared 30% and 40% identity with ure-
chistachykinin I and hyposin-H5, respectively. Moreover, we also
observed a sequence relationship between Cm-p1 and different
members of the hyposin family (Fig. 2). Additionally, similarity was
observed with Vesp-VB1 from the invertebrate V. bicolor, which
exhibits both antifungal and bactericidal activities (data not shown)
[38]. In all cases, we noted a conserved hydrophobic core (italicized
Table 1
Antifungal activity of Cm-p1 against different yeasts and mycelial fungi. The
minimum inhibitory concentration (MIC) [13] of the peptide is represented for each
fungus.
Microorganism Minimum Inhibitory
Concentration (mM)
Botrytis cinerea 20
Fusaryum oxysporum 20
Aspergillus niger 41
Candida albicans 01U 13
Candida albicans 38U 7
Candida parapsilosis 105
Cryptococcus neoformans L26 209
Cryptococcus neoformans L30 209
Trichophyton mentagrophytes e
Trichophyton rubrum 3
C. López-Abarrategui et al. / Biochimie 94 (2012) 968e974 971residues, Fig. 2). Furthermore, cationic residue number 10 (bold
type, Fig. 2), which ended the hydrophobic region, was also
conserved in all the antimicrobial peptides we analyzed. In parallel,
a similar puriﬁcation procedure was performed using the same
crude extract, and a peptide with an m/z value of 5282 was also
isolated (data not shown). This peptide, named Cm-p2, was
partially sequenced by automated Edman degradation and yielded
the sequence SESILIVHQQQSSRSSGS. Cm-p1 and Cm-p2 share 70%
identity between them, suggesting that they could be two
members of a single family of antimicrobial peptides or could be
signiﬁcantly correlated.
3.3. Antimicrobial activity
To demonstrate the antimicrobial activity of Cm-p1, the peptide
was synthesized in solid-phase. Despite the high bactericidal
activity of the C. muricatus crude extract, synthesized Cm-p1 was
incapable of inhibiting either the growth of Gram-negative bacteria
(E. coli and Klebsiella pneumoniae) or the development of Gram-
positive bacteria (S. aureus) (data not shown). Nevertheless,
a broad spectrum of antifungal activity was observed for the
synthetic peptide (Table 1). Cm-p1 was active against ﬁlamentous
fungi and yeasts of both medical and agricultural interest. As
Table 1 shows, a lower MIC was obtained against T. rubrum
(4 mg ml1), whereas a higher MIC was obtained against different
clinical isolates of C. neoformans (256 mg ml1).
3.4. Toxicity against mammalian cells
To evaluate the toxicity of Cm-p1 against mammalian cells,
different doses of the peptide were incubated in the presence of
human erythrocytes. No concentrations of Cm-p1 were capable of
provoking hemoglobin release (data not shown). Additionally, the
viability and proliferation of cultured RAW 264.7 cells incubated
with different doses of Cm-p1 were evaluated using the MTT
reagent. The viability and proliferation of RAW 264.7 cells were
unaffected by Cm-p1 (Fig. 3).
3.5. Theoretical structural analysis
Initial analyses show that Cm-p1 is a hydrophilic molecule
scoring a grand average of hydropathicity (GRAVY) of 0.830 and
exhibits a small central hydrophobic region ﬂanked by basic amino
acids at the extremes (Fig. 4). Furthermore, Cm-p1 is not an
amphipathic molecule, as was demonstrated by helix-wheel
projection using the tool wheel of Gromacs software (data not
shown). To improve peptide structure analyses, a three-
dimensional model of the hydrophilic Cm-p1 peptide was con-
structed (Fig. 4). The model exhibited a a-helix conformation when
generated by three different methodologies as previously described
before in session 2.11. The model constructed present cationic
arginines (Arg2 and Arg10) and histidine (His8) residues and also an
exposed hydrophobic region (Leu5eVal7) that favors a mem-
braneepeptide interaction (Figs. 2 and 4). The model shared 22%Fig. 2. Primary structure alignment of Cm-p1 and Cm-p2 against other antimicrobial pep
hydrophobic region, and bold residues correspond to the conserved cationic residues.identity with the neuropeptide PDB structure 2RMI [30]. A valida-
tion of the three-dimensional model of Cm-p1 by Ramachandran
plot showed that 100% of the modeled amino acid residues were in
physically acceptable regions for secondary structure formation in
relation to the torsion angles phi and psi. The z-score value given in
PROSA II was used to verify whether the input structure was within
the range of scores typically found for native proteins of similar
size. The z-score value was 1.36 and is comparable to NMR
structures of antimicrobial peptides of similar length, which have z-
scores of 1 to 1.5 [39e41]. The RMSD value obtained for Cm-p1
model acquired by using Modeller strategy was 1.7 Å. Moreover
when this helical model was comparedwithmodels constructed by
I-Tasser and HHPred servers, 0.8 Å RMSD values were obtained.
These values clear demonstrate the similar structural conformation
among all models proposed and strongly suggests a helical
conformation.4. Discussion
Functional studies have determined the residues or domains
that could be responsible for antimicrobial properties. In many
cases, the N-terminal region has been hypothesized to act as an
initial membrane anchor [42]. Although structural and functional
differences can be observed among the different antimicrobial
peptides, some properties could be very common, such as hydro-
phobicity and amphipathicity [16]. In this regard, Cm-p1 is not
a classical antimicrobial peptide. In fact, it is a small, hydrophilic
peptide; there is no clear evidence of the amphipathicity properties
that are commonly found in other antimicrobial peptides. Indeed,
of the 1755 peptides in the AMP database, only three have features
similar to Cm-p1. One of these, urechistachykinin I, is a neuropep-
tide derived from the invertebrate Urechis unicinctus that shares
30% identity with Cm-p1 [43]. This peptide exhibits a broad spec-
trum of antibacterial activity against the Gram-positive bacteria
Streptococcus mutans, S. aureus and Enterococcus faecium and the
Gram-negative bacteria E. coli O-157, Pseudomonas aeruginosa and
Vibrio vulniﬁcus with MIC values in the 10.6e42.5 mM range [43].
Despite the similarities between these peptides, Cm-p1 is not antides from different animal sources. Italicized residues correspond to the conserved
Fig. 3. Effects of Cm-p1 on RAW 264.7 murine macrophage-like cells viability.
Different concentrations of peptide were added to 1000 cells per well and incubated
for 72 h at 37 C in 5% CO2. Triton X-100 was used as a positive control for toxicity, and
PBS was used as a negative control. Cm-p1 were assayed at 200 mg ml1 (Cm-p1 200)
and at 400 mg ml1 (Cm-p1 400).
C. López-Abarrategui et al. / Biochimie 94 (2012) 968e974972antibacterial peptide, possibly due to its lower molecular charge
(þ1) in comparison to urechistachykinin I (þ2). Moreover, hyposin-
H5, an antimicrobial peptide identiﬁed from the skin secretions of
the frog Phyllomedusa hypochondrialis azurea [44], shares 40%
identity with Cm-p1. Despite the clear identity shared with hypo-
sins (Fig. 2), Cm-p1 exhibits different physiochemical properties,Fig. 4. Three-dimensional structural modeling of Cm-p1. Blue and red regions corre-
spond to the cationic and anionic areas, respectively. Labeled residues may be related
to the peptide’s possible mechanism of action. The structure was visualized using
PyMOL. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)such as hydrophobicity (GRAVY: 0.007) and net charge (þ4).
Another antimicrobial peptide that shares sequence similarity with
Cm-p1 is VESP-VB1. This peptide was isolated from the venom of
the wasp Vespa bicolor Fabricius. Interestingly, despite the low
cationicity of VESP-VB1 (þ1), this peptide exhibits antimicrobial
activity against different isolates of E. coli and S. aureus, possibly
due to the molecule’s hydrophobicity (GRAVY: 1.131) [38].
To conﬁrm that the Cm-p1 sequence was derived from C. mur-
icatus, we identiﬁed a parallel sequence (Cm-p2) that was part of
a larger peptide (5282 Da). Cm-p1 shared 70% identity with Cm-p2.
The divergence between these sequences could be attributed to the
existence of isoforms, which is relatively probable for AMPs, or
simply the fragmentation of similar peptides. Even with this
divergence, Cm-p1 could be interpreted as a closely related protein
sequence from C.muricatus. Taking into account that Cm-p1 ismore
positively charged and less hydrophilic than Cm-p2, we synthe-
sized Cm-p1 to explore its antimicrobial potential.
Although Cm-p1 was not capable of inhibiting bacterial
growth, even at high doses, it exhibited a broad spectrum anti-
microbial activity against fungi. The MIC values of Cm-p1 for yeast
and ﬁlamentous fungi were in the 4e256 mg ml1 range. The
peptide was less effective against the yeasts C. neoformans and
Candida parapsilosis. Interestingly, some echinocandins/pneumo-
candins are also less effective against these fungi [45]. Further-
more, it has been demonstrated that C. parapsilosis has developed
a major resistance to amphotericin-B compared to other Candida
species [46]. Taking into account the other evaluated yeast and
ﬁlamentous fungi, the range of MIC values was 4e50 mg ml1. This
range of effectiveness is similar to the antifungal activities re-
ported for other peptides [47,48]. Antimicrobial peptides that
primarily or exclusively have antifungal properties are less ubiq-
uitous than those with broad antimicrobial actions. Nevertheless,
both natural and synthetic peptides do exist that exhibit primarily
antifungal activity [48]. The plant defensins Hs-AFP1, Dm-AMP1
and Rs-ARF2 and the insect defensins heliomycin and drosomycin
belong to this group of peptides [49,50]. Furthermore, ure-
chistachykinin I is also capable of inhibiting fungal strains at
concentrations of 21.3e42.5 mM [43].
In addition to functional studies, theoretical modeling shows
that Cm-p1 could assume an a-helix conformation with a distribu-
tion of net charge (þ2) caused by exposed cationic arginine (Arg2
and Arg10) and histidine (His8) residues, which probably favor
a membraneepeptide interaction. Additionally, despite the hydro-
philicity of Cm-p1, the hydrophobic conserved region Leu5eVal7
seems to play a critical role in the peptide’s antifungal activity, as
has been previously demonstrated [51]. Moreover, the presence of
the amino acid residue Val7 might also be important in fungal
interaction. Several studies have demonstrated that an amidated
valine residue at the C-terminus had lethal effects against fungi and
a broad spectrum of pathogenic microorganisms [52].
One of the current antifungal therapeutic problems is the
toxicity of many approved drugs, such as amphotericin-B, echino-
candins and pneumocandins. For this reason, it is essential to
search for new antifungal molecules without toxicity against
mammalian cells. At the highest evaluated dose (256 mg ml1), Cm-
p1 showed no signs of toxicity against human red blood cells and
RAW 264.7 cells. This effect could be expected due to the low
hydrophobicity of Cm-p1. In fact, a correlation between hydro-
phobicity and hemolysis has been previously established. The
selectivity of antimicrobial peptides for microbial cells can be
signiﬁcantly increased by simply reducing the hydrophobicity of
the helix hydrophobic face [53,54].
The potential of peptide therapeutics has improved each year;
however, the production process appears to be a substantial chal-
lenge for the pharmaceutical industry, especially in the case of
C. López-Abarrategui et al. / Biochimie 94 (2012) 968e974 973peptides, which are expensive compounds to produce. In this
regard, the physiochemical properties of this peptide permit high
recovery yields after solid-phase synthesis, which makes it possible
to obtain large quantities of Cm-p1 by a procedure that is suitable
for large-scale downstream experiments. In summary, Cm-p1, the
peptide fragment identiﬁed in this study, features physiochemical
properties that suggest that it could be utilized in the near future
as a biotechnological tool. Cm-p1 has strong potential for the
development of an antifungal drug and clearly possesses the
potential to aid in the solution of both health and agribusiness
problems.Acknowledgments
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